lysophosphatidic acid has been researched along with alprostadil in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (66.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Butcher, RW; Clark, RB; Proll, MA | 1 |
| Clark, RB; Green, DA | 1 |
| Arreguin-Arevalo, A; Chon, M; Haberman, J; LaPorte, ME; Nett, TM; Randel, RD; Sy, T; Tsutahara, N; Weems, CW; Weems, YS | 1 |
3 other study(ies) available for lysophosphatidic acid and alprostadil
| Article | Year |
|---|---|
Phosphatidate and monooleylphosphatidate inhibition of fibroblast adenylate cyclase is mediated by the inhibitory coupling protein, Ni.
Topics: Adenosine Diphosphate Ribose; Adenylate Cyclase Toxin; Adenylyl Cyclase Inhibitors; Alprostadil; Carbachol; Cell Line; Cell Membrane; Cyclic AMP; Diglycerides; GTP-Binding Proteins; Humans; Lysophospholipids; Magnesium; Pertussis Toxin; Phosphatidic Acids; Phosphatidylcholines; Phosphatidylinositols; Platelet Activating Factor; Virulence Factors, Bordetella | 1985 |
Comparison of the muscarinic-cholinergic and lysophosphatidate inhibition of fibroblast adenylate cyclase demonstrating desensitization to the cholinergic stimulus.
Topics: Adenylyl Cyclase Inhibitors; Alprostadil; Atropine; Carbachol; Cyclic AMP; Epinephrine; Fibroblasts; Half-Life; Humans; Lysophospholipids; Phosphatidic Acids; Prostaglandins E; Receptors, Cholinergic; Receptors, Muscarinic | 1981 |
Effects of LPA2R, LPA3R, or EP4R agonists on luteal or endometrial function in vivo or in vitro and sirtuin or EP1R, EP2R, EP3R or EP4R agonists on endometrial secretion of PGE and PGF
Topics: Alprostadil; Animals; Corpus Luteum; Dinoprost; Endometrium; Female; Lysophospholipids; Progesterone; Prostaglandins E; Receptors, Lysophosphatidic Acid; Receptors, Prostaglandin E; Receptors, Prostaglandin E, EP4 Subtype; RNA, Messenger; Sheep; Sirtuins | 2017 |